Sino Biopharmaceutical Limited (BKK:SINOBIO19)

Thailand · Delayed Price · Currency is THB · Units

4.620

-0.100 (-2.12%)

Last updated: Sep 10, 2026, 4:28 PM ICT

Market Cap	466.66B
Revenue (ttm)	138.58B
Net Income	17.55B
EPS	0.97
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	0.10 (2.15%)
Ex-Dividend Date	Sep 1, 2026

Volume	94,931
Open	4.640
Previous Close	4.720
Day's Range	4.580 - 4.660
52-Week Range	3.600 - 5.500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 26, 2026

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules... [Read more]

Industry Pharmaceutical Preparations

Founded 2000

Employees 22,838

Stock Exchange Stock Exchange of Thailand

Ticker Symbol SINOBIO19